SRNE News and Press, Sorrento Therapeutics Inc. From 08/26/21

Sorrento Therapeutics (NASDAQ: SRNE) , a clinical-stage biopharmaceutical company, saw its shares rise more than 10% this week. The stock opened at $8.36 on Monday and rose to a high of $9.63 on Wednesday. The stock is up more than 32% this year and has been somewhat volatile in the...

Exclusive license for M P ro inhibitors supports rapidly growing small molecule development portfolio for combating COVID-19. Lead compound, MPI8, exhibited potent in vitro antiviral activity against SARS-CoV-2 and all of the major Variants of Concern (VoCs) (alpha, beta, ...

Sorrento’s mRNA vaccine (“STI-mRNA”) delivered with the MuVaxx™ Lymphatic Drug Delivery Device (“MuVaxx”), at 1/10th of the dose vs an LNP-mRNA reference standard 1 (“LNP-mRNA”) delivered intramuscularly (“IM”), dem...

M P ro is a SARS-CoV-2 enzyme that catalyzes the formation of a number of essential proteins for the viral reproduction. M P ro inhibitors block this catalytic process to potentially inhibit the viral replication in human cell hosts and prevent viral infection. T...

Rheumatoid Arthritis (RA) is one of many chronic autoimmune conditions affecting over 20 million people in the United States (NIH, 2017). Sofusa is a revolutionary technology which delivers biologic therapies through the skin and into the lymphatic system. Current biologic treat...

Immunization with a protein-based immunogen, DYAI-100, a receptor binding domain (RBD) of SARS-CoV-2, resulted in potent B cell immunity in preclinical studies, with strong serological recognition of the original SARS-CoV-2 virus and major variants of concern (Alpha, Beta, Gamma, and Delt...

PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), announced that, effective September 1, 2021, ZTlido® (lidocaine topical system) 1.8% has been added to multiple formularies, including two n...

XtalPi, a US-China AI-based drug discovery company, completed a $400 million Series D financing at an estimated valuation of $2 billion. Shanghai's HutchMed announced a $310 million deal to acquire greater China rights to Epizyme's epigenetic treatment for niche cancers. Advaccine...

Several stocks of companies hoping to make a big splash in the COVID-19 vaccine market soared this week. Shares of Novavax (NASDAQ: NVAX) were up 29.6% as of the market close on Thursday. Dynavax Technologies (NASDAQ: DVAX) stock jumped 19%. Sorrento Therapeutics (...

The Delta variant has demonstrated a likely course for our Covid future – a new endemic piece of the global human microbiome puzzle. It’s not the news we wanted. But it could have turned out a lot worse.  Covid is amenable to vaccine solutions, even if we may have to come u...